Trial Radar KI | ||
|---|---|---|
Die klinische Studie NCT06573593 für Alopecia Areata, Janus Kinase Inhibitors ist offene rekrutierung. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen. | ||
Eine Studie entspricht den Filterkriterien
Kartenansicht
Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study 150 Real-World-Daten
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT06573593 ist eine beobachtungsstudie zur Untersuchung von Alopecia Areata, Janus Kinase Inhibitors und hat den Status offene rekrutierung. Die Studie startete am 29. Juli 2024 und soll 150 Teilnehmer aufnehmen. Durchgeführt von Second Affiliated Hospital, School of Medicine, Zhejiang University ist der Abschluss für 31. Dezember 2026 geplant. Die Daten von ClinicalTrials.gov wurden zuletzt am 27. August 2024 aktualisiert.
Kurzbeschreibung
The introduction of Janus Kinase inhibitors (JAKi) seems to revolutionize the field of alopecia areata (AA) therapeutics. However, the ideal JAKi is not yet settled and the real-world data are still missing. To provide evidence about effectiveness and safety of different JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib in real-world settings and describe baseline disea...Mehr anzeigen
Offizieller Titel
Efficacy and Safety of JAK Inhibitors in Patients With Alopecia Areata: a Single-center, Real-world Study
Erkrankungen
Alopecia AreataJanus Kinase InhibitorsWeitere Studien-IDs
- 20240699
NCT-Nummer
Studienbeginn (tatsächlich)
2024-07-29
Zuletzt aktualisiert
2024-08-27
Studienende (vorauss.)
2026-12-31
Geplante Rekrutierung
150
Studientyp
Beobachtungsstudie
Status
Offene Rekrutierung
Studienarme/Interventionen
| Teilnehmergruppe/Studienarm | Intervention/Behandlung |
|---|---|
Tofacitinib treated group In the real-world settings, patients with AA treated with tofacitinib. | Tofacitinib In the real-world settings, patients with AA treated with tofacitinib. |
Baritinib treated group In the real-world settings, patients with AA treated with baritinib. | Baricitinib In the real-world settings, patients with AA treated with Baricitinib. |
Ruxolitinib treated group In the real-world settings, patients with AA treated with ruxolitinib | Ruxolitinib In the real-world settings, patients with AA treated with Ruxolitinib. |
Upadacitinib treated group In the real-world settings, patients with AA treated with upadacitinib. | Upadacitinib In the real-world settings, patients with AA treated with Upadacitinib. |
Abrocitinib treated group In the real-world settings, patients with AA treated with abhicitinib. | Abrocitinib In the real-world settings, patients with AA treated with Abrocitinib. |
Ritlecitinib treated group In the real-world settings, patients with AA treated with ritlecitinib. | Ritlecitinib In the real-world settings, patients with AA treated with Ritlecitinib. |
Hauptergebnismessungen
Nebenergebnismessungen
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Mean SALT | Reduction of Severity of Alopecia Tool (SALT) score compared with baseline | at week 24 |
SALT50 | Percentage of patient with more than 50% improvement in SALT score | at week 24 |
SALT75 | Percentage of patient with more than 70% improvement in SALT score | at week 24 |
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Mean SALT | Reduction of Severity of Alopecia Tool (SALT) score compared with baseline | at week 12, 36, 48, 56 |
SALT50 | Percentage of patient with more than 75% improvement in SALT score | at week 12, 36, 48, 56 |
SALT75 | Percentage of patient with more than 50% improvement in SALT score | at week 12, 36, 48, 56 |
Safety profile | Any adverse events including infection, hypohepatia, thrombus, gastrointestinal reaction and any other system events. | at week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56 |
Teilnahme-Assistent
Eignungskriterien
Zugelassene Altersgruppen
Kind, Erwachsene, Ältere Erwachsene
Mindestalter
2 Years
Zugelassene Geschlechter
Alle
- Patients with alopecia areata between 2 to 18 years old
- Patients diagnosed with alopecia areata according to AA guideline
- AA Patients treated with JAKi including tofacitinib, baricitinib, ritlecitinib，abrocitinib, upadacitinib and ifidancitinib for more than 3 months
- Patients had previously received hair implants
- Other alopecia
- Other diseases may induce alopecia including psoriasis, lichen planus, et al.
- Unable to estimate SALT score at baseline or at follow-up
- Patients are participating in other clinical trials
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityZentrale Studienkontakte
Kontakt: Ru Dai, MD, 15982215914, [email protected]
Kontakt: Wu, [email protected]
1 Studienstandorte in 1 Ländern
Zhejiang
Second Affiliated Hospital, School of Medicine, Zhejiang University, China, Hangzhou, Zhejiang, 310009, China
Ru Dai, Ph.D, Kontakt, 86 15982215914, [email protected]
Offene Rekrutierung